Skip to content
GenoLensGenoLens

IGSF1

Chr Xq26.1

immunoglobulin superfamily member 1

Aliases:
KIAA0364, IGDC1, IGCD1, INHBP, MGC75490
MANE:
ENST00000361420.8

Annotations refreshed 10 hours ago.

Predicted protein structure

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

  • Congenital hypothyroidism

    X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
  • DDG2P

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • Pituitary hormone deficiency

    X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)
  • Fetal anomalies

    X-LINKED: hemizygous mutation in males, biallelic mutations in females
  • Intellectual disability

    X-LINKED: hemizygous mutation in males, biallelic mutations in females

Disease associations (Open Targets)

  • X-linked central congenital hypothyroidism with late-onset testicular enlargement

    0.78
  • neurodegenerative disease

    0.52
  • hereditary disease

    0.47
  • post-traumatic stress disorder

    0.39
  • Macroorchidism

    0.38
  • Central hypothyroidism

    0.38
  • hypopituitarism

    0.34
  • cancer

    0.08
  • neoplasm

    0.08
  • Combined pituitary hormone deficiencies, genetic forms

    0.07

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Immunoglobulin superfamily member 1

Seems to be a coreceptor in inhibin signaling, but seems not to be a high-affinity inhibin receptor. Antagonizes activin A signaling in the presence or absence of inhibin B (By similarity). Necessary to mediate a specific antagonistic effect of inhibin B on activin-stimulated transcription

Data sources: HGNC (CC BY 4.0), AlphaFold (CC BY 4.0, Jumper et al. Nature 2021), Genomics England PanelApp (CC BY 4.0), ClinGen, Open Targets (CC0), UniProt.

Not for sole clinical decision-making. Always verify against primary sources.